SCHEMBL5409280

SCHEMBL5409280

O=C(O)CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccccc1C(=O)NCc1c(F)cccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.44
NPC1 O15118 2/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 3/20 0.40
MAPK14 Q16539 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
KCNA5 P22460 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5402400 0.95 RAB9A (0.44) RAB9ANPC1CHRNB2CHRNB4CHRNA3
SCHEMBL5409102 0.93 ALDH1A1 (0.47) RAB9ANPC1CHRNB2CHRNB4CHRNA3
SCHEMBL5395784 0.93 ALDH1A1 (0.43) RAB9ANPC1CHRNB2CHRNB4CHRNA3
SCHEMBL5403086 0.91 KCNK3 (0.46) RAB9AALDH1A1KMT2AHDAC1KCNA5
SCHEMBL5394224 0.91 HTT (0.50) ALDH1A1KMT2AMAPK1HTT
SCHEMBL5409270 0.91 TDP1 (0.44) RAB9ANPC1CHRNB2CHRNB4CHRNA3
SCHEMBL5392428 0.90 CA1 (0.48) KMT2AHTT
SCHEMBL5406613 0.89 FFAR1 (0.41) RAB9ANPC1ALDH1A1KMT2AKCNA5
SCHEMBL5412218 0.89 RAB9A (0.56) RAB9AALDH1A1KMT2AKCNA5TDP1
SCHEMBL5401156 0.88 RAB9A (0.49) RAB9AALDH1A1KMT2AHDAC1KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB RAB9A 3132/4885NPC1 740/4885CHRNB2 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.